An organic compound having the structure of Formula (I), shown below, is disclosed. When used in a hole injection layer or a hole transporting layer, it can greatly improve the balance of electron holes and electron transporting of a device, thereby bringing excellent device effects, for example, improving the efficiency and lifetime of a device. At the same time, it also achieves a good effect when the organic compound having the structure of Formula (I) is used as a P-type conductive doping material in a charge generation layer of a multi-layer OLED device. ##STR00001##

An organic compound having the structure of Formula (I), shown below, is disclosed. When used in a hole injection layer or a hole transporting layer, it can greatly improve the balance of electron holes and electron transporting of a device, thereby bringing excellent device effects, for example, improving the efficiency and lifetime of a device. At the same time, it also achieves a good effect when the organic compound having the structure of Formula (I) is used as a P-type conductive doping material in a charge generation layer of a multi-layer OLED device. ##STR00001##

Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug. ##STR00001##

Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug. ##STR00001##

The disclosure relates to new compounds, including bifunctional compounds, to be used as modulators of ubiquitination for targeted protein degradation.

Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (II).

Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (II).

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.

##STR00001##

Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.

##STR00001##

Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.